DexCom (DXCM) Stock Overview
A medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
DXCM Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
DexCom, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$52.70 |
| 52 Week High | US$87.21 |
| 52 Week Low | US$49.45 |
| Beta | 1.52 |
| 1 Month Change | -7.67% |
| 3 Month Change | -18.81% |
| 1 Year Change | -17.10% |
| 3 Year Change | -54.42% |
| 5 Year Change | n/a |
| Change since IPO | -43.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| DXCM | AT Medical Equipment | AT Market | |
|---|---|---|---|
| 7D | -10.6% | 0.5% | 2.4% |
| 1Y | -17.1% | 3.6% | 28.1% |
Return vs Industry: DXCM underperformed the Austrian Medical Equipment industry which returned 3.1% over the past year.
Return vs Market: DXCM underperformed the Austrian Market which returned 29.6% over the past year.
Price Volatility
| DXCM volatility | |
|---|---|
| DXCM Average Weekly Movement | 6.4% |
| Medical Equipment Industry Average Movement | 5.2% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in AT Market | 5.4% |
| 10% least volatile stocks in AT Market | 1.9% |
Stable Share Price: DXCM's share price has been volatile over the past 3 months compared to the Austrian market.
Volatility Over Time: DXCM's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Austrian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 10,250 | Jake Leach | www.dexcom.com |
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes.
DexCom, Inc. Fundamentals Summary
| DXCM fundamental statistics | |
|---|---|
| Market cap | €20.53b |
| Earnings (TTM) | €627.87m |
| Revenue (TTM) | €3.93b |
Is DXCM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DXCM income statement (TTM) | |
|---|---|
| Revenue | US$4.52b |
| Cost of Revenue | US$1.85b |
| Gross Profit | US$2.67b |
| Other Expenses | US$1.94b |
| Earnings | US$720.70m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.85 |
| Gross Margin | 59.01% |
| Net Profit Margin | 15.96% |
| Debt/Equity Ratio | 89.8% |
How did DXCM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/04 21:26 |
| End of Day Share Price | 2025/11/04 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DexCom, Inc. is covered by 53 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Johnson | Baird |
| Travis Steed | Barclays |
| Matthew Miksic | Barclays |